Loading stock data…
PHAT
$12.87+0.86 (+7.16%)
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Phathom Pharmaceuticals, Inc. in the Healthcare sector is trading at $12.87. The stock is currently 30% below its 52-week high of $18.31, remaining 2.2% above its 200-day moving average. Technical signals show neutral RSI of 51 and bearish MACD signal, explaining why PHAT maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 51) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$12.87
Potential Upside
5%
Whystock Fair Value$13.51
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Mean target$23.70+84.1%
Range$13.00 – $29.00
Fundamentals
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$965.87M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.61
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
75.35%
Volume
Today's trading volume
1.94M
Recent News
How The Phathom Pharmaceuticals (PHAT) Narrative Is Shifting Around Profitability And Exclusivity Risks
Price targets on Phathom Pharmaceuticals have been refreshed in recent reports, with some moving to US$25 and others to US$13 as analysts rework their models. These updated targets reflect a mix of optimism around the company’s stated goal of reaching profitability in early Q3 2026, along with caution around long term exclusivity, regulatory factors, and commercialization efforts. As you read on, you will see how to interpret these shifting targets and track the evolving Street narrative...
Phathom Pharmaceuticals Q1 Earnings Call Highlights
Phathom Pharmaceuticals (NASDAQ:PHAT) reported first-quarter 2026 net revenue of $58.3 million, more than doubling the $28.5 million recorded in the same period a year ago, as the company emphasized continued progress in deepening adoption of its acid-suppression medicine VOQUEZNA among gastroentero
Phathom Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Moby summary of Phathom Pharmaceuticals, Inc.'s Q1 2026 earnings call
Phathom (PHAT) Q1 2026 Earnings Transcript
Hello, everyone, and thank you for joining us this morning to discuss Phathom's first quarter 2026 results. This morning's presentation will include remarks from Steve Basta, our President and CEO; and Sanjeev Narula, our Chief Financial and Business Officer. Before we begin, let me remind you that we will be making a number of forward-looking statements throughout today's presentation.
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -5.88% and +2.76%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?